NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the clinical activity of the combination of fluorouracil,
leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced
biliary tract cancers following gemcitabine and platinum chemotherapy.